Compare Heron Therapeutics Inc (HRTX) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Vistra Corp — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Vistra Corp trades at $158.76 (market cap $55.96B). The key difference: Vistra Corp is far larger — about 755.8× Heron Therapeutics Inc's market cap, and Vistra Corp pays a 0.55% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Vistra Corp for 32 Days on average.
| HRTX | VST | |
|---|---|---|
Market Cap | $74.04M | $55.96B |
Volume | 3,668,095 | 11,969,036 |
Sector | Health | Utilities |
52-Week High | $1.49 | $210.85 |
52-Week Low | $0.27 | $134.71 |
Typical Hold Time | 35 Days | 32 Days |
Enterprise Value | $180.78M | $77.89B |
Dividend Yield | — | 0.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Vistra Corp. (VST) trades at $166.72, up 3.88% today, with a bullish technical signal and strong analyst support. The stock shows robust profitability with a net income margin of 11.55% and ROE of 75.73%, though earnings have been mixed recently. Recent developments include a $4.2 billion US loan to boost nuclear power and a 20-year power deal with New Era Energy, positioning Vistra to capitalize on AI-driven electricity demand.
Outlook is positive given strategic positioning in AI power infrastructure, but risks include earnings volatility and high valuation multiples. The consensus price target of $215.23 implies significant upside, supported by institutional interest and favorable sector trends. Investors should weigh growth prospects against execution risks and market sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
